{"id":"W2240656553","doi":"10.1200/jco.2007.25.18_suppl.14046","title":"Preliminary results of a phase II study of continuous low dose metronomic (LDM) cyclophosphamide (CTX) and celecoxib (CEL) for asymptomatic hormone refractory prostate cancer (HRPC) with assessment of anti-angiogenic biomarkers","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Celecoxib; Angiogenesis; Prostate cancer; Asymptomatic; Internal medicine; Cancer; Cyclophosphamide; Chemotherapy; Clinical endpoint; Oncology; Cancer research; Pharmacology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003008715,0.001844381,0.002134175,0.0004347341,0.000681487,0.00110485,0.001250263,0.001981647,0.004403632],"category_scores_gemma":[0.00157445,0.0007383075,0.001274407,0.0004335418,0.001125982,0.0009728836,0.000376924,0.003724988,0.001053784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009042486,"about_ca_system_score_gemma":0.003101409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002204719,"about_ca_topic_score_gemma":0.005782844,"domain_scores_codex":[0.9992223,0.0003716411,0.00003877371,0.00009154471,0.00008978863,0.0001858734],"domain_scores_gemma":[0.9980234,0.0003385243,0.0001854278,0.0001300502,0.0001425703,0.001180061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5626099,0.2537308,0.01020899,0.0009194554,0.001254538,0.0007226709,0.0007577521,0.002581888,0.0763276,0.0003433657,0.006919242,0.08362395],"study_design_scores_gemma":[0.264942,0.7103574,0.01605437,0.00002425386,0.000279501,0.0003673661,0.00005399111,0.0006480539,0.004185512,0.0001656073,0.002890853,0.00003109566],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978808,0.00172986,0.001950482,0.001029956,0.0002037306,0.01046389,0.002447589,0.0001706168,0.003195944],"genre_scores_gemma":[0.9651894,0.001698498,0.005512373,0.002305995,0.0003914284,0.01065596,0.005705113,0.00006609337,0.008475089],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004403632,"threshold_uncertainty_score":0.01591176,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03252530381420718,"score_gpt":0.4220794838803343,"score_spread":0.3895541800661272,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}